Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, Ipilimumab, Nivolumab, and hSRT in Symptomatic Melanoma Brain Metastases
NCT06163820Phase 2Recruiting
- Start
- Aug 2026
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in melanoma brain metastases (MBM). Started Aug 2026; status: recruiting.
02
Drugs
bevacizumab
03
Conditions
melanoma brain metastases (MBM)
Beyond the preview
Go deeper on NCT06163820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06163820.